Serum paraoxonase 1 activity in women with metabolic syndrome

Kardiologia Polska

Volumn 68, Issue 11, 2010, Pages 1219-1224

  Yilmaz, Hale ^a   Sayar, Nurten ^a   Yilmaz, Mehmet ^a   Gurkan, Ufuk ^a   Sesal, Cenk ^b   Tosu, Rodi ^a   Cakmak, Nazmiye ^a   Erer, Betul ^a   Oz, Dilaver ^a   Ciloglu, Figen ^c   Bolca, Osman ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c GenLab Genetic Medical Laboratories Istanbul   (Turkey)

Author keywords

Coronary artery disease; Metabolic syndrome; Paraoxonase activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PATHOGENESIS; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; WOMEN'S HEALTH;

EID: 78650114674     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497.
2. Navab M, Hama SY, Anantharamaiah GM et al. Normal high density lipoprotein inhibits three steps in the formation of mild-ly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res, 2000; 41: 1495-1508.
3. Primo-Parmo SL, Sorenson RC, Teiber J et al. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 1996; 33: 498-507. (Pubitemid 26159866)
4. Schwartz CJ, Valente AJ, Sprague EA et al. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care, 1992; 15: 1156-1167.
5. Lyons TJ, Li W, Wells-Knecht MC et al. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes, 1994; 43: 1090-1095. (Pubitemid 124005173)
6. Kobayashi K, Watanabe J, Umeda F et al. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J, 1995; 42: 461-465.
7. Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis, 1991; 86: 193-199.
8. Abbott CA, Mackness MI, Kumar S et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol, 1995; 15: 1812-1818.
9. Lerman A, Sopko G. Women and cardiovascular heart disease: clinical implications from the Women's Ischemia Syndrome Evaluation (WISE) study. Are we smarter? J Am Coll Cardiol, 2006; 47: 59-62.
10. Zeller M, Steg PG, Ravisy J et al. Observatoire des Infarctus de Côte-d'Or Survey Working Group. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med, 2005; 165: 1192-1198.
11. Sadeghian S, Darvish S, Salimi S et al. Metabolic syndrome: stronger association with coronary artery disease in young men in comparison with higher prevalence in young women. Coron Artery Dis, 2007; 18: 163-168.
12. Kozan O, Oguz A, Abaci A et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr, 2007; 61: 548-553.
13. Ozsahin AK, Gokcel A, Sezgin N et al. Prevalence of the metabolic syndrome in a Turkish adult population. Diabet Nutr Metab, 2004; 17: 230-234.
14. Sclavo M. Cardiovascular risk factors and prevention in women: similarities and differences. Ital Heart J, 2001; 2: 125-141.
15. Onat A, Sansoy V. Metabolic syndrome, major culprit of coronary disease among turks: its prevalence and impact on coronary risk. Arch Turk Soc Cardiol, 2002; 30: 8-15.
16. American Diabetes Associaton. Standards of medical care in diabetes 2009. Diabetes Care, 2009; 32: 13-61.
17. Sanghera DK, Saha N, Asten CE et al. Genetic polymorphism of paraoxonase and the risk of coronary heart diseases. Arterioscler Thromb Vasc Biol, 1997; 17: 1067-1073. (Pubitemid 27260325)
18. Khader Y, Khatatbeh M, El-Salem K et al. The metabolic syndrome among patients undergoing cardiac catheterization in Jordan. J Cardiometab Syndr, 2008; 3: 24-28.
19. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg, 2008; 70: 193-219.
20. Ayub A, Mackness MI, Arrol S et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol, 1999; 19: 330-335.
21. Hansel B, Giral P, Nobecourt E et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab, 2004; 89: 4963-4971. (Pubitemid 39391435)
22. Tabur S, Torun AN, Sabuncu T et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol, 2010; 162: 535-541
23. Lagos KG, Filippatos TD, Tsimihodimos V et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids, 2009; 44: 9-16.
24. Kopprasch S, Pietzsch J, Kuhlisch E et al. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab, 2003; 88: 1711-1716. (Pubitemid 36623393)
25. Singh S, Venketesh S, Verma JS et al. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease and type 2 diabetes mellitus. Indian J Med Res, 2007; 125: 783-787. (Pubitemid 47364465)
26. Sozmen B, Delen Y, Girgin FK et al. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clin Biochem, 1999; 32: 423-427.
27. Saha N, Roy AC, Teo SH et al. Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins. Clin Genet, 1991; 40: 277-282.
28. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol, 1995; 15: 89-95.
29. Cakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med, 2008; 8: 51-57.
30. Lopes NH, Paulitsch FS, Pereira AC et al. Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. Coron Artery Dis, 2008; 19: 383-388.
31. McElveen J, Mackness MI, Colley CM et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem, 1986; 32: 671-673.
32. Szabo I, Rona K, Czinner A et al. Is paraoxon hydrolytic activity in serum predictive of myocardial infarction? Clin Chem, 1987; 33: 742-743.
33. Gugliucci A, Mehlhaff K, Kinugasa E et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta, 2007; 377: 213-220. (Pubitemid 44920216)